Oncolytics establishes $75M at-the-market equity offering to fund pelareorep trials

Filed April 6, 2026 · Period ending April 6, 2026 · ~1 min read

Key Changes

• high

  Company entered into agreement with Jefferies to sell up to $75M of common stock through at-the-market offerings, with 3% commission on sales. No obligation to sell any shares.

  Item 8.01 verify on EDGAR →
• medium

  Proceeds will fund clinical development of pelareorep and related R&D expenses, plus operating costs and working capital.

  Item 8.01 verify on EDGAR →
• low

  Shelf registration statement became effective April 3, 2026, enabling the ATM program.

  Item 8.01 verify on EDGAR →